Resources

The Plasma Protein Therapeutics Association (PPTA) represents the manufacturers of plasma-derived and recombinant analog therapies (collectively, “plasma protein therapies”) as well as plasma donation centers who collect source plasma. These therapies are used by people worldwide to treat a variety of rare diseases and serious medical conditions. PPTA members provide about 80 percent of the plasma protein therapies for the United States market.

The Plasma Protein Therapeutics Association (PPTA) would like to thank you for authoring Assembly Bill 392.

The journal publication, “Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment,” is authored by Professor Philippe van Wilder with the Université libre de Bruxelles and Professor Esther de Vries of Tilburg University and offers a health economic model to estimate the value of treatment with IG therapy for CVID patients.

The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM).